On Nov 09, major Wall Street analysts update their ratings for $Ligand Pharmaceuticals (LGND.US)$, with price targets ranging from $135 to $150.
Barclays analyst Balaji Prasad maintains with a buy rating, and adjusts the target price from $125 to $150.
Oppenheimer analyst Leland Gershell maintains with a buy rating, and adjusts the target price from $135 to $147.
Oppenheimer analyst Trevor Allred initiates coverage with a buy rating, and sets the target price at $147.
Craig-Hallum analyst Matt Hewitt maintains with a buy rating, and sets the target price at $140.
Benchmark Co. analyst Robert Wasserman maintains with a buy rating, and adjusts the target price from $110 to $135.
Furthermore, according to the comprehensive report, the opinions of $Ligand Pharmaceuticals (LGND.US)$'s main analysts recently are as follows:
Following a quarter that outperformed expectations and led to raised forecasts, it's noted that the company's positive outlook is supported by robust performance across its three principal revenue channels.
Ligand's third-quarter financial outcomes surpassed expectations on the revenue front, and the company has elevated its full-year revenue forecast for fiscal year 2024 to a range of $160 million to $165 million. This projection is deemed cautious by analysts in light of the robust performance of royalty assets, coupled with the acceleration of early product launches and the possibility of expanded usage for various indications.
Here are the latest investment ratings and price targets for $Ligand Pharmaceuticals (LGND.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月9日，多家华尔街大行更新了$Ligand Pharmaceuticals (LGND.US)$的评级，目标价介于135美元至150美元。
巴克莱银行分析师Balaji Prasad维持买入评级，并将目标价从125美元上调至150美元。
奥本海默控股分析师Leland Gershell维持买入评级，并将目标价从135美元上调至147美元。
奥本海默控股分析师Trevor Allred首予买入评级，目标价147美元。
Craig-Hallum分析师Matt Hewitt维持买入评级，目标价140美元。
本臻力行分析师Robert Wasserman维持买入评级，并将目标价从110美元上调至135美元。
此外，综合报道，$Ligand Pharmaceuticals (LGND.US)$近期主要分析师观点如下：
以下为今日5位分析师对$Ligand Pharmaceuticals (LGND.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
